Vantive

Vantive is a vital organ therapy company formed in 2025 as an independent business following its spin-off from Baxter International. The company develops products, digitally-enhanced solutions and advanced services for dialysis, delivered both at home and in clinical settings, and for kidney and other vital organ support in intensive care units. Its stated mission is to extend lives and expand possibilities for patients and care teams globally.

Its portfolio spans home dialysis therapies and in-clinic dialysis products, critical care therapies for ICU use, and digital solutions and advanced services intended to improve patient experience, care team efficiency and clinical outcomes. Remote patient monitoring technology forms a significant part of the digital offering; the company reports that such monitoring is associated with lower mortality rates, fewer hospitalisations, reduced treatment drop-out and greater treatment adherence among home dialysis patients.

Technical work at Vantive sits across dialysis therapies, kidney care, critical care and vital organ support, remote patient monitoring, digital health, medical devices, and healthcare data and software. The company serves more than 100 countries and reports over 1 million daily touchpoints with patients worldwide, building on a 70-year legacy in kidney care innovation. Vantive maintains a presence in both home-based and hospital/clinical care settings.